Eye-Tracking Test Enters into the Running for an Alzheimer’s Screen
One in nine Americans aged 65 and older has Alzheimer's disease, a fatal brain disorder with no cure or effective treatment. Therapy could come in the form of new drugs, but some experts suspect drug trials have failed so far because compounds were tested too late in the disease's progression. By the time people show signs of dementia, their brains have lost neurons. No therapy can revive dead cells, and little can be done to create new ones. So researchers running trials now seek participants who still pass as cognitively normal but are of decline. These “preclinical” Alzheimer's patients may represent a window of opportunity for therapeutic intervention. How to identify such individuals before they have symptoms presents a challenge, however. Today most Alzheimer's patients are diagnosed after a detailed medical workup and extensive tests that gauge mental function. Other tests, such as spinal fluid analyses and positron-emission tomography (PET) scans, can detect sig...